Open Journal of Medical Psychology
2023
John R. Rossiter
1 citation
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therapeutic Goods Administration, is planning to allow approved psychiatrists, as of July 1, 2023, to prescribe psilocybin to treat depression and MDMA to treat post-traumatic stress disorder, a move precipitated by the U.S. Food and Drug Administration’s...
Drug Science, Policy and Law
2023
Jaden Brandt
5 citations
The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the legislative policy arena to conceptualize how future reforms, policy creation, and clinical practice should occur to broaden access to these agents while simultaneously maximizing effectiveness and mitigating harm. The pharmacy profession has...
Journal of Psychoactive Drugs
2023
Otto Simonsson, Simon B. Goldberg
37 citations
There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative...
Journal of Psychoactive Drugs
2023
Zachary Herrmann, Mitch Earleywine, Joseph A. de Leo et al.
19 citations
Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions to psychedelic molecules are particularly interesting given how they covary with subsequent improvements associated with psychedelic-assisted treatments. Although links between subjective reactions and decreases in treatment-resistant clinical...
American Journal of Geriatric Psychiatry
2023
C Bree Johnston, Maria Mangini, Charles S. Grob et al.
33 citations
Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorder. Psychedelics also have properties that could help provide therapeutic benefits for patients...
Journal of Psychoactive Drugs
2023
Daniel J. Kruger, Nicolas G. Glynos, Christopher W Fields et al.
10 citations
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use of and harm reduction practices for psychedelics in the naturalistic use landscape. The current study piloted an assessment instrument with questions on legal status, therapeutic potential, and side effects of psychedelics among people reporting...
Journal of Psychopharmacology
2023
Brent M Kious, Zach Schwartz, Benjamin R. Lewis
44 citations
Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the difficulty of ensuring adequate blinding, the relative overrepresentation in studies of participants who have previously used psychedelics, and the importance of personal experience with psychedelics for those who provide psychedelic-assisted therapy....
Perspectives in biology and medicine
2023
Gail A. Edelsohn, Dominic Sisti
8 citations
Recent clinical trials of psychedelic drugs aim to treat a range of psychiatric conditions in adults. MDMA and psilocybin administered with psychotherapy have received FDA designation as "breakthrough therapies" for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) respectively. Given the potential benefit for minors burdened with many of the same disorders, calls...
Journal of Psychopharmacology
2023
Jack E Henningfield, Judy Ashworth, David J Heal et al.
13 citations
Background: Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct. Findings: Key...
International journal of clinical and health psychology : IJCHP
2023
John R. Kelly, Gerard Clarke, Andrew Harkin et al.
33 citations
Moving towards a systems psychiatry paradigm embraces the inherent complex interactions across all levels from micro to macro and necessitates an integrated approach to treatment. Cortical 5-HT2A receptors are key primary targets for the effects of serotonergic psychedelics. However, the therapeutic mechanisms underlying psychedelic therapy are complex and traverse molecular, cellular, and...